Please login to the form below

Not currently logged in
Email:
Password:

Genfit

This page shows the latest Genfit news and features for those working in and with pharma, biotech and healthcare.

FDA delays decision on Intercept's NASH drug by three months

FDA delays decision on Intercept's NASH drug by three months

Intercept is trailed by Genfit, which is due to release late-phase data on its candidate this quarter, and a large pack of companies with earlier-phase candidates.

Latest news

  • Northsea Therapeutics raises $40m to develop fish oil NASH drug Northsea Therapeutics raises $40m to develop fish oil NASH drug

    French pharma Genfit also has a candidate being studied in NASH in a phase 3 trial, with interim results due in the next few months.

  • Genfit presses the gas on NASH with combo trials Genfit presses the gas on NASH with combo trials

    It will enrol patients with suspected NASH and significant to advanced fibrosis, measured using non-invasive diagnostic tools including Genfit’s own NIS4 diagnostic test for NASH. ... Dean Hum. “NASH is a multifaceted cardio-metabolic disease

  • Genfit claims FDA breakthrough status for liver disease drug Genfit claims FDA breakthrough status for liver disease drug

    Elafibranor has shown promising anticholestatic effects in a Phase 2 clinical trial,” said Pascal Birman, Deputy Chief Medical Officer, Genfit. ... Genfit’s drug has been shown to reduce this however, operating as a dual agonist of the peroxisome

  • Genfit launches $135m IPO to back NASH plans Genfit launches $135m IPO to back NASH plans

    Trailing rivals Intercept in race to market. Genfit has priced its initial public offering (IPO) in the US as it looks to raise $135m to help advance its drug for ... Another $35m earmarked for pivotal trials in primary biliary cirrhosis, a rare

  • Liver specialist Genfit files $120m IPO on Nasdaq Liver specialist Genfit files $120m IPO on Nasdaq

    French biotech Genfit has pressed the button on a public listing in the US, seeking to raise around $120m to help it fund development of lead liver disease drug elafibranor. ... Genfit is offering five million shares at $26.33 on the Nasdaq Global Market

More from news
Approximately 4 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics